Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 13/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9831561 | 0.85 | NOD1 (0.62) | NOD1HDAC2SLC6A5CA2GNPAT | |
| SCHEMBL6668178 | 0.85 | NOD1 (0.62) | NOD1HDAC2SLC6A5CA2GNPAT | |
| SCHEMBL9469762 | 0.84 | NOD1 (0.67) | NOD1HDAC2SLC6A5GNPAT | |
| SCHEMBL9469765 | 0.84 | NOD1 (0.67) | NOD1HDAC2SLC6A5GNPAT | |
| SCHEMBL9831553 | 0.83 | NOD1 (0.75) | NOD1HDAC2SLC6A5GNPAT | |
| SCHEMBL1006347 | 0.83 | NOD1 (0.60) | NOD1HDAC2SLC6A5CA2GNPAT | |
| SCHEMBL31039943 | 0.83 | NOD1 (0.70) | NOD1HDAC2SLC6A5GNPAT | |
| SCHEMBL9831556 | 0.83 | NOD1 (0.75) | NOD1HDAC2SLC6A5GNPAT | |
| SCHEMBL7176522 | 0.81 | NOD1 (0.58) | NOD1HDAC2SLC6A5CA2GNPAT | |
| SCHEMBL7176520 | 0.81 | NOD1 (0.58) | NOD1HDAC2SLC6A5CA2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| EP-3082872-B1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200157240-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | MEDIMMUNE LIMITED (GB) | 2020-05-21 | — | — | US | disclosed |
| US-20160310611-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC. (US) | 2016-10-27 | — | — | US | disclosed |
| EP-3082872-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | Genentech, Inc. (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2357006-B1 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2015095124-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| EP-2353611-B1 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| US-8906376-B2 | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease | SEATTLE GENETICS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-1545613-B9 | AURISTATIN CONJUGATES AND THEIR USE FOR TREATING CANCER, AN AUTOIMMUNE DISEASE OR AN INFECTIOUS DISEASE | SEATTLE GENETICS INC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20030162953-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY | 2003-08-28 | — | — | US | disclosed |
| US-20020107389-A1 | Conjugates of chemically defined non-polymeric valency platform molecules and biologically active molecules | LA JOLLA PHARMACEUTICAL COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020082400-A1 | Conjugates of T cell epitope deficient immunogen analogs for humoral anergy and chemically defined non-polymeric valency platform molecules | LA JOLLA PHARMACEUTICAL COMPANY | 2002-06-27 | — | — | US | disclosed |
| EP-0722318-A4 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | JOLLA PHARMA (US) | 1998-08-05 | — | — | EP | disclosed |
| US-5633395-A | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1997-05-27 | — | — | US | disclosed |
| US-5606047-A | INCLUDES POLYNUCLEOTIDE DUPLEXES THAT HAVE SIGNIFICANT BINDING ACTIVITY FOR LUPUS ANTIBODIES | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1997-02-25 | — | — | US | disclosed |
| US-5552391-A | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0722318-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL (US) | 1996-07-24 | — | — | EP | disclosed |
| WO-1995007073-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1995-03-16 | — | — | WO | disclosed |
| EP-0642798-A2 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 1995-03-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157240-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, LNPEP, VIP | NOD1 1643/4885HDAC2 4165/4885ASAH1 1265/4885 |
| US-20020082400-A1 | Conjugates of T cell epitope deficient immunogen analogs for humoral anergy and chemically defined non-polymeric valency platform molecules | SSB, CD4, LY96 | NOD1 1680/4885HDAC2 2952/4885ASAH1 3847/4885 |
| US-20030162953-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | SSB, PCNA, NCL | NOD1 1621/4885HDAC2 1728/4885ASAH1 2358/4885 |
| US-20020107389-A1 | Conjugates of chemically defined non-polymeric valency platform molecules and biologically active molecules | SSB, PCNA, NASP | NOD1 1354/4885HDAC2 1653/4885ASAH1 2065/4885 |
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | DNPEP, LNPEP, VIP | NOD1 1643/4885HDAC2 4165/4885ASAH1 1265/4885 |
| US-20160310611-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | DNPEP, BCR, LNPEP | NOD1 1580/4885HDAC2 4061/4885ASAH1 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.